Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610951 | 0.92 | CHRM1 (0.67) | CHRM1 | |
| Oxalic Acid SCHEMBL7609511 | 0.83 | CHRM1 (0.84) | CHRM1 | |
| Oxalic Acid SCHEMBL7617389 | 0.82 | CHRM1 (0.53) | CHRM1 | |
| Oxalic Acid SCHEMBL7612666 | 0.82 | CHRM1 (0.65) | CHRM1 | |
| Oxalic Acid SCHEMBL7619202 | 0.80 | CHRM1 (0.68) | CHRM1 | |
| SCHEMBL5931786 | 0.77 | CHRM1 (0.57) | CHRM1 | |
| Oxalic Acid SCHEMBL7609554 | 0.77 | CHRM1 (0.61) | CHRM1 | |
| SCHEMBL7612125 | 0.74 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL6915452 | 0.73 | CHRM1 (0.60) | CHRM1 | |
| SCHEMBL6916467 | 0.73 | CHRM1 (0.74) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5750541-A | 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | disclosed |
| US-5712297-A | COGNITION ACTIVATORS; ALZHEIMER*S DISEASE | NOVO NORDISK A/S (DK) | 1998-01-27 | — | — | US | disclosed |
| EP-0788357-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1997-08-13 | — | — | EP | disclosed |
| US-5565475-A | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives | MUHLHAUSER MARK A (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0734259-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | disclosed |
| EP-0687265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
| US-5284859-A | Analgesics, Alzheimer's disease | NOVO NORDISK A/S (DK) | 1994-02-08 | — | — | US | disclosed |
| US-5264444-A | Cognition activators | NOVO NORDISK A/S (DK) | 1993-11-23 | — | — | US | disclosed |
| US-5260311-A | Cognition activators, analgesics for sever pain, glaucoma treatment | NOVO NORDISK A/S (DK) | 1993-11-09 | — | — | US | disclosed |
| US-5041455-A | Stimulants of cognitive function in mammals | NOVO NORDISK A/S (DK) | 1991-08-20 | — | — | US | disclosed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | disclosed |